Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sevabertinib: First Approval.

Drugs - 1 May 2026

Keam Susan J

Abstract excerpt

Sevabertinib (HYRNUO®), an oral, reversible, small molecule tyrosine kinase inhibitor (TKI) of human epidermal growth factor receptor 2 (HER2) that also shows activity against epidermal growth factor receptor (EGFR), is being developed by Bayer for the treatment of solid tumours with mutations in HER2 or EGFR genes. Sevabertinib is derived from Bayer's strategic research alliance with the Broad Institute of MIT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Approval

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erb-b2 Receptor Tyrosine Kinases

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to United States

Source

Identifiers

PMID: 41882473
DOI: 10.1007/s40265-026-02299-w

Genes

EGFR
ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sevabertinib: First Approval.PMID 41882473Read ↗

Befotertinib: First Approval.Semantic proximity Read ↗

Zongertinib: First Approval.Semantic proximity Read ↗

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Furmonertinib: First Approval.Semantic proximity Read ↗

Sunvozertinib: First Approval.Semantic proximity Read ↗

Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.Semantic proximity Read ↗

Sugemalimab: First Approval.Semantic proximity Read ↗

Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).Semantic proximity Read ↗

Fulzerasib: First Approval.Semantic proximity Read ↗

First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.Semantic proximity Read ↗

LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohortsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.